Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...

Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings ...

新泽西州拉威 - 全球医疗保健领导者默沙东集团（NYSE: MRK）已完成收购Curon Biopharmaceutical的新型双特异性抗体CN201，从而增强其管线中用于治疗B细胞恶性肿瘤和自身免疫性疾病的潜在药物。这笔交易涉及约7.5亿美元的预付款和相关费用，将反映在默沙东集团第三季度的非GAAP业绩中。

2024年9月30日，制药公司默沙东（MRK）成交额为12.43亿美元，在当日美股中排第43名，成交额较昨日减少8.20%，当日成交量为1095.00万。 默沙东（MRK）于2024年9月30日跌0.12%，报113.55美元，该股过去5个交易日跌1.80%，整个9月跌4.14%，年初至今涨4.16%，过去52周涨10.30%。

On Friday, Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $113.69 which represents a slight increase of $0.60 or 0.53% from the prior close of $113.09. The stock opened at $113.17 ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...